Chen M, Zhang H, Zhang G, Zhong A, Ma Q, Kai J et al (2018) Targeting TPX2 suppresses proliferation and promotes apoptosis via repression of the PI3k/AKT/P21 signaling pathway and activation of p53 pathway in breast cancer. Biochem Biophys Res Commun 507:74–82. https://doi.org/10.1016/j.bbrc.2018.10.164

Article  PubMed  Google Scholar 

Chen Z, Xie H, Hu M, Huang T, Hu Y, Sang N et al (2020) Recent progress in treatment of hepatocellular carcinoma. Am J Cancer Res 10:2993–3036

PubMed  PubMed Central  Google Scholar 

Demir T, Lee SS, Kaseb AO (2021) Systemic therapy of liver cancer. Adv Cancer Res 149:257–294. https://doi.org/10.1016/bs.acr.2020.12.001

Article  PubMed  Google Scholar 

Deng Q, Wang Q, Zong WY, Zheng DL, Wen YX, Wang KS et al (2010) E2F8 contributes to human hepatocellular carcinoma via regulating cell proliferation. Cancer Res 70:782–791. https://doi.org/10.1158/0008-5472.Can-09-3082

Article  PubMed  Google Scholar 

Ding L, Zhang S, Chen S, Zheng L, Xiao L (2019) Effect and mechanism of lentivirus-mediated silencing of TPX2 gene on proliferation and apoptosis of human hepatoma cells. J Cell Biochem 120:8352–8358. https://doi.org/10.1002/jcb.28119

Article  PubMed  Google Scholar 

Ganapathy-Kanniappan S, Geschwind JF (2013) Tumor glycolysis as a target for cancer therapy: progress and prospects. Mol Cancer 12:152. https://doi.org/10.1186/1476-4598-12-152

Article  PubMed  PubMed Central  Google Scholar 

Hu J, He Q, Tian T, Chang N, Qian L (2023) Transmission of exosomal TPX2 promotes metastasis and resistance of NSCLC Cells to Docetaxel. Onco Targets Ther 16:197–210. https://doi.org/10.2147/ott.S401454

Article  PubMed  PubMed Central  Google Scholar 

Huang Y, Guo W, Kan H (2014) TPX2 is a prognostic marker and contributes to growth and metastasis of human hepatocellular carcinoma. Int J Mol Sci 15:18148–18161. https://doi.org/10.3390/ijms151018148

Article  PubMed  PubMed Central  Google Scholar 

Kong J, Xu S, Zhang P, Wang Y (2023) Transcription factor E2F8 promotes cisplatin resistance in hepatocellular carcinoma by regulating DNA damage via NUSAP1. Int J Toxicol 42:420–429. https://doi.org/10.1177/10915818231182114

Article  PubMed  Google Scholar 

Ladd AD, Duarte S, Sahin I, Zarrinpar A (2024) Mechanisms of drug resistance in HCC. Hepatology 79:926–940. https://doi.org/10.1097/hep.0000000000000237

Article  PubMed  Google Scholar 

Liang B, Jia C, Huang Y, He H, Li J, Liao H et al (2015) TPX2 level correlates with hepatocellular carcinoma cell proliferation, apoptosis, and EMT. Dig Dis Sci 60:2360–2372. https://doi.org/10.1007/s10620-015-3730-9

Article  PubMed  Google Scholar 

Liu Q, Tu K, Zhang H, Zheng X, Yao Y, Liu Q (2015) TPX2 as a novel prognostic biomarker for hepatocellular carcinoma. Hepatol Res 45:906–918. https://doi.org/10.1111/hepr.12428

Article  PubMed  Google Scholar 

Long N, Chu L, Jia J, Peng S, Gao Y, Yang H et al (2020) CircPOSTN/miR-361-5p/TPX2 axis regulates cell growth, apoptosis and aerobic glycolysis in glioma cells. Cancer Cell Int 20:374. https://doi.org/10.1186/s12935-020-01454-x

Article  PubMed  PubMed Central  Google Scholar 

Lu Y, Zhang J, Li L, Li S, Yang Z (2020) Carcinogenesis effects of E2F transcription factor 8 (E2F8) in hepatocellular carcinoma outcomes: an integrated bioinformatic report. Biosci Rep. https://doi.org/10.1042/BSR20193212

Marengo A, Rosso C, Bugianesi E (2016) Liver cancer: connections with obesity, fatty liver, and cirrhosis. Annu Rev Med 67:103–117. https://doi.org/10.1146/annurev-med-090514-013832

Article  PubMed  Google Scholar 

Matson DR, Denu RA, Zasadil LM, Burkard ME, Weaver BA, Flynn C et al (2021) High nuclear TPX2 expression correlates with TP53 mutation and poor clinical behavior in a large breast cancer cohort, but is not an independent predictor of chromosomal instability. BMC Cancer 21:186. https://doi.org/10.1186/s12885-021-07893-7

Article  PubMed  PubMed Central  Google Scholar 

Meng X, Cao J, Zheng H, Ma X, Wang Y, Tong Y et al (2023) TPX2 promotes ovarian tumorigenesis by interacting with Lamin A/C and affecting its stability. Cancer Med 12:9738–9748. https://doi.org/10.1002/cam4.5683

Article  PubMed  PubMed Central  Google Scholar 

Miwa T, Kokuryo T, Yokoyama Y, Yamaguchi J, Nagino M (2015) Therapeutic potential of targeting protein for Xklp2 silencing for pancreatic cancer. Cancer Med 4:1091–1100. https://doi.org/10.1002/cam4.453

Article  PubMed  PubMed Central  Google Scholar 

Neumayer G, Belzil C, Gruss OJ, Nguyen MD (2014) TPX2: of spindle assembly, DNA damage response, and cancer. Cell Mol Life Sci 71:3027–3047. https://doi.org/10.1007/s00018-014-1582-7

Article  PubMed  PubMed Central  Google Scholar 

Ognibene M, Podesta M, Garaventa A, Pezzolo A (2019) Role of GOLPH3 and TPX2 in neuroblastoma DNA damage response and cell resistance to chemotherapy. Int J Mol Sci. https://doi.org/10.3390/ijms20194764

Article  PubMed  PubMed Central  Google Scholar 

Schmid I, Häberle B, Albert MH, Corbacioglu S, Fröhlich B, Graf N et al (2012) Sorafenib and cisplatin/doxorubicin (PLADO) in pediatric hepatocellular carcinoma. Pediatr Blood Cancer 58:539–544. https://doi.org/10.1002/pbc.23295

Article  PubMed  Google Scholar 

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A et al (2021) Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71:209–249. https://doi.org/10.3322/caac.21660

Article  PubMed  Google Scholar 

Wang F, Zhao W, Gao Y, Zhou J, Li H, Zhang G et al (2019) CDK5-mediated phosphorylation and stabilization of TPX2 promotes hepatocellular tumorigenesis. J Exp Clin Cancer Res 38:286. https://doi.org/10.1186/s13046-019-1297-6

Article  PubMed  PubMed Central  Google Scholar 

Wang Y, Wang H, Yan Z, Li G, Hu G, Zhang H et al (2020) The critical role of dysregulated Hh-FOXM1-TPX2 signaling in human hepatocellular carcinoma cell proliferation. Cell Commun Signal 18:116. https://doi.org/10.1186/s12964-020-00628-4

Article  PubMed  PubMed Central  Google Scholar 

Wang H, Chu F, Zhang XF, Zhang P, Li LX, Zhuang YL et al (2023a) TPX2 enhances the transcription factor activation of PXR and enhances the resistance of hepatocellular carcinoma cells to antitumor drugs. Cell Death Dis 14:64. https://doi.org/10.1038/s41419-022-05537-7

Article  PubMed  PubMed Central  Google Scholar 

Wang T, Zhang F, Zhang P (2023b) Role of the TPX2/NCOA5 axis in regulating proliferation, migration, invasion and angiogenesis of breast cancer cells. Exp Ther Med 25:304. https://doi.org/10.3892/etm.2023.12003

Article  PubMed  PubMed Central  Google Scholar 

Wang H, Chen W, Qi Y, Liu D, Liu Z, Zhang Q et al (2023c) miR-29c suppresses the malignant phenotype of hepatocellular carcinoma cells in vitro by mediating tpx2 associated with immune infiltration. Dig Dis Sci 68:1923–1935. https://doi.org/10.1007/s10620-022-07810-3

Article  PubMed  Google Scholar 

Wang L, Zhang H, Li Y, Li L (2024) TPX2 influences the regulation of macrophage polarization via the NF-κB pathway in lung adenocarcinoma. Life Sci 340:122437. https://doi.org/10.1016/j.lfs.2024.122437

Article  PubMed  Google Scholar 

Wen N, Cai Y, Li F, Ye H, Tang W, Song P et al (2022) The clinical management of hepatocellular carcinoma worldwide: a concise review and comparison of current guidelines: 2022 update. Biosci Trends 16:20–30. https://doi.org/10.5582/bst.2022.01061

Article  PubMed  Google Scholar 

Wittmann T, Boleti H, Antony C, Karsenti E, Vernos I (1998) Localization of the kinesin-like protein Xklp2 to spindle poles requires a leucine zipper, a microtubule-associated protein, and dynein. J Cell Biol 143:673–685. https://doi.org/10.1083/jcb.143.3.673

Article  PubMed  PubMed Central  Google Scholar 

Xu J, Shen J,